

ORASURE TECHNOLOGIES INC  
Form 8-K  
April 07, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): April 6, 2011**

**OraSure Technologies, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**001-16537**  
(Commission

File Number)

**36-4370966**  
(I.R.S. Employer

Identification No.)

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

**220 East First Street**

**Bethlehem, Pennsylvania**  
(Address of Principal Executive Offices)

**Registrant's telephone number, including area code: 610-882-1820**

**18015-1360**  
(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.**

On April 5, 2011, Jack Goldstein, Ph.D. retired as a member of the OraSure Technologies, Inc. (the Company) Board of Directors (the Board).

On April 6, 2011, Stephen S. Tang, Ph.D. was appointed as a new member of the Board. Dr. Tang was also appointed to serve on the Audit Committee and Compensation Committee of the Board. Pursuant to the Company's 2000 Stock Award Plan, Dr. Tang was granted an option to purchase 40,000 shares of the Company's common stock with an exercise price equal to the mean between the high and low sales prices of the Company's common stock on the date of his appointment. The foregoing option will vest on a monthly basis over the 24-month period following the grant date. Vesting will be accelerated in the event of a change in control involving the Company.

A press release, dated April 7, 2011, announcing Dr. Goldstein's retirement and Dr. Tang's appointment to the Board, is attached as Exhibit 99 to this Report and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
99	Press Release, dated April 7, 2011, announcing the retirement of Jack Goldstein, Ph.D. as a member of the Company's Board of Directors and the appointment of Stephen S. Tang, Ph.D. as a member of the Company's Board.

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: April 7, 2011

By: */s/ Jack E. Jerrett*  
Jack E. Jerrett  
Senior Vice President, General Counsel and Secretary

**Index to Exhibits**

**Exhibit  
No.**

**Description**

99 Press Release, dated April 7, 2011, announcing the retirement of Jack Goldstein, Ph.D. as a member of the Company's Board of Directors and the appointment of Stephen S. Tang, Ph.D. as a member of the Company's Board.